Bolt Biotherapeutics Q2 net loss narrows on restructuring and lower research activity
BOLT•Outlook and clinical progress
-
Bolt expects initial clinical data from BDC-4182 Phase 1/2 study with 3Q 2026 results
-
Company anticipates cash balance will fund operations into 1Q 2027
-
LOWER EXPENSES - Co said R&D and G&A expenses declined mainly due to restructuring and reduced research activity
-
CLINICAL TRIAL PROGRESS - Co said ongoing BDC-4182 Phase 1/2 study in gastric and gastroesophageal cancer advanced to Cohort 4
Q2 results and cost reductions
- US cancer immunotherapy developer's Q2 collaboration revenue fell sharply from prior year
- Net loss narrowed yr/yr on lower R&D and G&A expenses after restructuring
- Company expects cash to fund operations into Q1 2027
| Metric | Beat/Miss | Actual | Consensus Estimate |
| Q2 Collaboration Revenue | $5,000 | ||
| Q2 Net Loss | $7.72 mln | ||
| Q2 Income from Operations | -$8.37 mln | ||
| Q2 Loss Per Basic Share | $4.57 | ||
| Q2 Operating Expenses | $8.38 mln |
